Plain-English translation of NCT05774509 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called extracellular vesicles from cardiovascular progenitor cells—tiny molecules secreted by heart-repair cells—delivered directly into the bloodstream. Researchers believe these molecules may help the heart heal itself in people with dilated cardiomyopathy (a weakened heart) who have not improved with standard medications.
People with severe, non-ischemic dilated cardiomyopathy often do not respond well enough to current medications and have few other options. This trial is exploring whether this new treatment could help by delivering repair molecules directly to damaged heart tissue.
If you enroll, you will receive three intravenous infusions of the treatment spaced over time. The trial uses a step-up design, meaning the first group of 4 patients receives a lower dose to confirm safety before a second group of 8 patients receives a higher dose. You will have regular follow-up visits and heart imaging tests to monitor how well the treatment works and to watch for any side effects.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
France